Is TECH a good stock to buy right now?

Based on our 6-factor quantitative model, BIO-TECHNE Corp (TECH) receives a "Reduce" rating with a composite score of 39.7/100. It is ranked #3,044 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 40/100, Momentum 34/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for TECH?

BIO-TECHNE Corp (TECH) has a "Reduce" rating and 2-star score. The composite score of 39.7 ranks it #3,044 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is TECH in?

BIO-TECHNE Corp operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $8.37 billion. It is classified as a mid-cap stock.

Does TECH pay a dividend?

Yes, TECH pays a dividend with a current yield of 0.58%. For every $1,000 invested, you would receive approximately $5.80 in annual dividend income.

What is TECH's P/E ratio?

TECH has a trailing P/E ratio of 63.62x. The Healthcare sector average is 23.6x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is TECH?

TECH's quality factor score is 50/100. Gross margin: 65.3%. ROE: 6.6% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is TECH valued compared to peers?

TECH's value factor score is 40/100 (higher = cheaper). Key multiples: P/E 63.6x, EV/EBITDA 46.6x. Valuation is roughly in line with peers.

What is TECH's debt level?

TECH's debt-to-equity ratio is 25%. Sector average: 32%. Low leverage suggests conservative financial management.

TECH has a beta of 1.19, meaning it tracks the market. Stability score: 56/100.

Does TECH have high short interest?

TECH's short interest factor score is 11/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

TECH Stock Analysis: Top Mid-Cap Reduce (Score 39.7/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
TECH	-0.05%	+4.54%	+5.15%	-5.56%	+12.75%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	+0.01%	+0.93%	+4.81%	-5.20%	-16.78%	-	-	-
Alpha vs Sector	+1.30%	+4.20%	+8.96%	-0.72%	+3.54%	-	-	-

Metric	TECH	Benchmark
P/E Ratio	63.6x	+169%
EV/EBITDA	46.6x	+635%
Price / Book	4.2x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
TECH BIO-TECHNE Corp	40	50	40	34	63.6x	6.6%	65.3%	11.2%	-2.5%	25.0x	$8.4B

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017
Gross Margin %	0.7%	0.6%	0.6%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%
Operating Margin %	0.2%	0.2%	0.1%	0.2%	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%
EBITDA Margin %	0.2%	0.2%	0.1%	0.2%	0.3%	0.3%	0.3%	0.5%	0.3%	0.3%	0.3%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.3%	0.2%	0.1%	0.3%	0.1%	0.2%	0.1%
FCF Margin %	-	-	-	-	-	-	33.1%	20.8%	21.9%	23.2%	22.8%
ROE %	0.1%	0.0%	0.0%	0.1%	0.1%	0.2%	0.1%	0.2%	0.1%	0.1%	0.1%
ROA %	0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%
ROIC %	7.1%	2.1%	4.2%	7.9%	12.0%	13.8%	11.0%	7.8%	7.4%	8.3%	7.5%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Gross Margin %

0.7%

0.6%

0.7%

Operating Margin %

0.2%

0.1%

0.2%

0.3%

0.2%

EBITDA Margin %

0.2%

0.1%

0.2%

0.3%

0.5%

0.3%

Net Margin %

0.1%

0.3%

0.2%

0.1%

0.3%

0.1%

0.2%

0.1%

FCF Margin %

33.1%

20.8%

21.9%

23.2%

22.8%

ROE %

0.1%

0.0%

0.1%

0.2%

0.1%

0.2%

0.1%

ROA %

0.1%

0.0%

0.1%

0.0%

ROIC %

7.1%

2.1%

4.2%

7.9%

12.0%

13.8%

11.0%

7.8%

7.4%

8.3%

7.5%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$1.2B	$1.2B	$1.2B	$1.1B	$1.1B	$931M	$739M	$714M	$643M	$563M	$499M	$452M
	—	$429M	$389M	$367M	$349M	—	—	—	—	—	—	—
	$777M	$790M	$770M	$770M	$756M	$633M	$483M	$473M	$432M	$375M	$337M	$307M
Gross Margin	65.3%	64.8%	66.4%	67.7%	68.4%	68.0%	65.4%	66.3%	67.2%	66.5%	67.5%	67.9%
	—	$589M	$466M	$378M	$373M	—	—	—	—	—	—	—
Research & Development	—	—	—	—	—	$71M	$65M	$62M	$55M	$54M	$45M	$41M
Depreciation	—	—	—	—	—	$88M	$83M	$78M	$64M	$60M	$43M	$37M
Total Operating Expenses	—	$688M	$563M	$471M	$460M	—	—	—	—	—	—	—
	$181M	$102M	$207M	$299M	$297M	$237M	$157M	$147M	$136M	$121M	$151M	$147M
EBIT	$181M	$102M	$207M	$299M	$297M	$237M	$157M	$147M	$136M	$121M	$151M	$147M
EBITDA	$181M	$102M	$207M	$299M	$297M	$249M	$378M	$211M	$200M	$179M	$192M	$192M
Operating Margin	15.3%	8.4%	17.8%	26.3%	26.8%	25.5%	21.3%	20.5%	21.2%	21.4%	30.2%	32.5%
EBITDA Margin	15.2%	8.4%	17.8%	26.3%	26.8%	26.8%	51.1%	29.6%	31.1%	31.8%	38.4%	42.5%
	—	—	—	$11M	$11M	$14M	$19M	$22M	$10M	$7M	$2M	$2M
	—	$98M	$186M	$339M	$301M	—	—	—	—	—	—	—
Income Tax Expense	—	$25M	$18M	$53M	$38M	$9M	$47M	$16M	-$198K	$36M	$43M	$46M
	$132M	$73M	$168M	$285M	$263M	$140M	$229M	$96M	$126M	$76M	$104M	$108M
Net Margin	11.2%	6.0%	14.5%	25.1%	23.8%	15.0%	31.0%	13.5%	19.6%	13.5%	20.9%	23.8%
	$0.24	$0.47	$1.07	$1.81	$6.93	$3.62	$6.00	$2.54	$3.36	$2.04	$2.81	$2.90
Diluted EPS	$0.24	$0.46	$1.05	$1.76	$6.63	$3.62	$6.00	$2.54	$3.36	$2.04	$2.81	$2.90
Weighted Avg Basic	—	158M	158M	157M	39M	—	—	—	—	—	—	—
Weighted Avg Diluted	—	160M	161M	162M	41M	—	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$1.2B

$1.1B

$931M

$739M

$714M

$643M

$563M

$499M

$452M

—

$429M

$389M

$367M

$349M

—

$777M

$790M

$770M

$756M

$633M

$483M

$473M

$432M

$375M

$337M

$307M

Gross Margin

65.3%

64.8%

66.4%

67.7%

68.4%

68.0%

65.4%

66.3%

67.2%

66.5%

67.5%

67.9%

—

$589M

$466M

$378M

$373M

—

Research & Development

—

$71M

$65M

$62M

$55M

$54M

$45M

$41M

Depreciation

—

$88M

$83M

$78M

$64M

$60M

$43M

$37M

Total Operating Expenses

—

$688M

$563M

$471M

$460M

—

$181M

$102M

$207M

$299M

$297M

$237M

$157M

$147M

$136M

$121M

$151M

$147M

EBIT

$181M

$102M

$207M

$299M

$297M

$237M

$157M

$147M

$136M

$121M

$151M

$147M

EBITDA

$181M

$102M

$207M

$299M

$297M

$249M

$378M

$211M

$200M

$179M

$192M

Operating Margin

15.3%

8.4%

17.8%

26.3%

26.8%

25.5%

21.3%

20.5%

21.2%

21.4%

30.2%

32.5%

EBITDA Margin

15.2%

8.4%

17.8%

26.3%

26.8%

51.1%

29.6%

31.1%

31.8%

38.4%

42.5%

—

$11M

$14M

$19M

$22M

$10M

$7M

$2M

—

$98M

$186M

$339M

$301M

—

Income Tax Expense

—

$25M

$18M

$53M

$38M

$9M

$47M

$16M

-$198K

$36M

$43M

$46M

$132M

$73M

$168M

$285M

$263M

$140M

$229M

$96M

$126M

$76M

$104M

$108M

Net Margin

11.2%

6.0%

14.5%

25.1%

23.8%

15.0%

31.0%

13.5%

19.6%

13.5%

20.9%

23.8%

$0.24

$0.47

$1.07

$1.81

$6.93

$3.62

$6.00

$2.54

$3.36

$2.04

$2.81

$2.90

Diluted EPS

$0.24

$0.46

$1.05

$1.76

$6.63

$3.62

$6.00

$2.54

$3.36

$2.04

$2.81

$2.90

Weighted Avg Basic

—

158M

157M

39M

—

Weighted Avg Diluted

—

160M

161M

162M

41M

—

BIO-TECHNE Corp (TECH) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does BIO-TECHNE Corp Do?

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. BIO-TECHNE Corp (TECH) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Charles R. Kummeth and employs approximately 3,000 people, headquartered in MINNEAPOLIS, Minnesota. With a market capitalization of $8.4B, TECH is one of the notable companies in the Healthcare sector.

BIO-TECHNE Corp (TECH) Stock Rating — Reduce (April 2026)

As of April 2026, BIO-TECHNE Corp receives a Reduce rating with a composite score of 39.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TECH ranks #3,044 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, BIO-TECHNE Corp ranks #444 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TECH Stock Price and 52-Week Range

BIO-TECHNE Corp (TECH) currently trades at $55.55. The stock lost $0.02 (0.0%) in the most recent trading session. The 52-week high for TECH is $72.16, which means the stock is currently trading -23.0% from its annual peak. The 52-week low is $46.01, putting the stock 20.7% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is TECH Overvalued or Undervalued? — Valuation Analysis

BIO-TECHNE Corp (TECH) carries a value factor score of 40/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 63.62x, compared to the Healthcare sector average of 23.63x — a premium of 169%. The price-to-book ratio stands at 4.19x, versus the sector average of 2.75x. The price-to-sales ratio is 7.09x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TECH trades at 46.58x EV/EBITDA, versus 6.34x for the sector.

Overall, TECH's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

BIO-TECHNE Corp Profitability — ROE, Margins, and Quality Score

BIO-TECHNE Corp (TECH) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 6.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 5.3% versus the sector average of -33.1%.

On a margin basis, BIO-TECHNE Corp reports gross margins of 65.3%, compared to 71.5% for the sector. The operating margin is 15.3% (sector: -66.1%). Net profit margin stands at 11.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -2.5% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

TECH Debt, Balance Sheet, and Financial Health

BIO-TECHNE Corp has a debt-to-equity ratio of 25.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.54x, indicating strong short-term liquidity.

TECH has a beta of 1.19, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for BIO-TECHNE Corp is 56/100, reflecting average volatility within the normal range for its sector.

BIO-TECHNE Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, BIO-TECHNE Corp reported revenue of $1.19B and earnings per share (EPS) of $0.24. Net income for the quarter was $132M. Gross margin was 65.3%. Operating income came in at $181M.

In Q2 2026, BIO-TECHNE Corp reported revenue of $296M and earnings per share (EPS) of $0.24. Net income for the quarter was $38M. Gross margin was 64.6%. Operating income came in at $54M.

In Q1 2026, BIO-TECHNE Corp reported revenue of $287M and earnings per share (EPS) of $0.25. Net income for the quarter was $38M. Gross margin was 65.6%. Revenue grew -1.0% year-over-year compared to Q1 2025. Operating income came in at $48M.

In FY 2025, BIO-TECHNE Corp reported revenue of $1.22B and earnings per share (EPS) of $0.47. Net income for the quarter was $73M. Gross margin was 64.8%. Revenue grew 5.2% year-over-year compared to FY 2024. Operating income came in at $102M.

Over the past 8 quarters, BIO-TECHNE Corp has demonstrated a growth trajectory, with revenue expanding from $303M to $1.19B. Investors analyzing TECH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TECH Dividend Yield and Income Analysis

BIO-TECHNE Corp (TECH) currently pays a dividend yield of 0.6%. At this yield, a $10,000 investment in TECH stock would generate approximately $$58.00 in annual dividend income. The net margin of 11.2% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

TECH Momentum and Technical Analysis Profile

BIO-TECHNE Corp (TECH) has a momentum factor score of 34/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 11/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TECH vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, BIO-TECHNE Corp (TECH) ranks #444 out of 838 stocks based on the Blank Capital composite score. This places TECH in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TECH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TECH vs S&P 500 (SPY) comparison to assess how BIO-TECHNE Corp stacks up against the broader market across all factor dimensions.

TECH Next Earnings Date

No upcoming earnings date has been announced for BIO-TECHNE Corp (TECH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TECH? — Investment Thesis Summary

The quantitative profile for BIO-TECHNE Corp suggests caution. Momentum is weak at 34/100, a headwind for near-term performance.

In summary, BIO-TECHNE Corp (TECH) earns a Reduce rating with a composite score of 39.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TECH stock.

Related Resources for TECH Investors

Explore more research and tools: TECH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TECH head-to-head with peers: TECH vs AZN, TECH vs SLGL, TECH vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $54

Unpacking Q4 Earnings: Thermo Fisher (NYSE:TMO) In The Context Of Other Research Tools & Consumables Stocks

How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story

Assessing Bio-Techne (TECH) Valuation After COMET Spatial Biology Platform Expansion

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

BIO-TECHNE Corp (TECH) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does BIO-TECHNE Corp Do?

BIO-TECHNE Corp (TECH) Stock Rating — Reduce (April 2026)

TECH Stock Price and 52-Week Range

Is TECH Overvalued or Undervalued? — Valuation Analysis

BIO-TECHNE Corp Profitability — ROE, Margins, and Quality Score

TECH Debt, Balance Sheet, and Financial Health

BIO-TECHNE Corp Revenue and Earnings History — Quarterly Trend

TECH Dividend Yield and Income Analysis

TECH Momentum and Technical Analysis Profile

TECH vs Competitors — Healthcare Sector Ranking and Peer Comparison

TECH Next Earnings Date

Should You Buy TECH? — Investment Thesis Summary

Related Resources for TECH Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $54

Unpacking Q4 Earnings: Thermo Fisher (NYSE:TMO) In The Context Of Other Research Tools & Consumables Stocks

How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story

Assessing Bio-Techne (TECH) Valuation After COMET Spatial Biology Platform Expansion